WC
TAK icon

Whitnell & Co’s Takeda Pharmaceutical TAK Stock Holding History

Whitnell & Co’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$10K Hold
511
– – ﹤0.01% 258
2019
Q3 		$9K Hold
511
– – ﹤0.01% 256
2019
Q2 		$9K Hold
511
– – ﹤0.01% 238
2019
Q1 		$10K Buy
+511
New +$10.3K ﹤0.01% 240

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Whitnell & Co's TAK Position: Q4 2019 in Review

Whitnell & Co held its Takeda Pharmaceutical (TAK) position steady in Q4 2019 at 511 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #258.

Whitnell & Co first reported a position in TAK in Q1 2019 and has held it in 4 quarters since. 339 funds tracked by Wall St. Rank hold TAK as of Q4 2019.

  • Whitnell & Co held 511 shares of Takeda Pharmaceutical worth $10K as of Q4 2019.
  • Whitnell & Co left its Takeda Pharmaceutical share count unchanged in Q4 2019.
  • Takeda Pharmaceutical made up ﹤0.01% of Whitnell & Co's portfolio in Q4 2019, its #258 holding.
  • Whitnell & Co first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 4 quarters since.
  • 339 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2019.

Based on Whitnell & Co's 13F filing for Q4 2019, filed 11 Feb 2020.